Media Releases

ClareonAutonoMe IOL and Delivery System Launched

Australian Ophthalmologists trialling Alcon’s ClareonAutonoMe intraocular lens (IOL) and delivery system have been impressed with its ease of use and the visual outcomes.

Alcon’s ClareonAutonoMe intraocular lens (IOL) and delivery system is an advanced monofocal IOL with the “first and only automated, disposable, preloaded IOL delivery system”. It builds on the success of Alcon’s AcrySof Platform, which has been implanted over 100 million times worldwide.2,3

REDUCED TIME AND RISKS

Dr. Smita Agarwal said the pre-loaded IOL delivery system reduces device preparation time and total case time by avoiding manual loading of the lens. Additionally, she said, “The pre-loaded Alcon platform has definitely reduced the risk of scratching the lens which could potentially happen if not handled carefully in the theatre. The risk of lens contamination and hence post-surgical infections are minimised. It is also very easy for the nurses to prime and in my hands, the longer nozzle helps lens insertion, either wound assisted or through a wound of 2.3 mm,” she added.

THE ALCON CLAREON AUTONOME INTRAOCULAR LENS AND DELIVERY SYSTEM.

SHORT LEARNING CURVE

Drs. Agarwal, Lawless and Wolfe all agreed that the ClareonAutonoMe delivery system was easy to learn to use.

Dr. Agarwal said she felt comfortable with the new delivery system and in control of the speed of insertion after performing just five cases. “I had to hold the lens insertor a bit more perpendicularly than has been the case previously, to ensure the lens went into the bag. Lens delivery was very smooth and it unfolded more quickly in the eye. Occasionally, during aspiration the port sticks to the optic due to the tacky nature of the material. However, the lens doesn’t get scratched while aligning it in the bag,” she said.

“Dr. Agarwal said her patients have found their vision to be brighter and clearer with the new Clareon IOL”

SUCCESSFUL PATIENT RESULTS

Dr. Agarwal said her patients have found their vision to be brighter and clearer with the new Clareon IOL. “I have used this lens in the second eye of some patients and they do not report any glare postoperatively,” she said.

FURTHER ADVANCES AWAITED

If Alcon lives up to Dr. Agarwal’s experience, this is likely to happen sooner rather than later. “Alcon always involves surgeons when they come up with new technology and listens to any feedback. This platform, with its consistent and smooth delivery system, has again demonstrated their commitment to optimising the surgical experience for surgeons,” she said.

 

References:

Alcon data on file, 2017, Schematic Model Eye and In Vitro Evaluation of Positive Dysphotopsia or Glare Types Photic Phenomena.
Alcon Data On File, AcrySof Units Sold-1993-2017.
2016 MS Global IOL Market Report.